| scholarly article | Q13442814 |
| P50 | author | Arun Kapoor | Q56807955 |
| P2093 | author name string | Ravit Arav-Boger | |
| Ran He | |||
| Gary H Posner | |||
| Michael Forman | |||
| Sujayita Roy | |||
| Jennifer R Mazzone | |||
| P2860 | cites work | Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4 | Q28266936 |
| An artemisinin-derived dimer has highly potent anti-cytomegalovirus (CMV) and anti-cancer activities | Q28476748 | ||
| Antiviral Drug Resistance of Human Cytomegalovirus | Q30430427 | ||
| Novel antitumor artemisinin derivatives targeting G1 phase of the cell cycle | Q31805177 | ||
| An artesunate-containing antimalarial treatment regimen did not suppress cytomegalovirus viremia | Q33678775 | ||
| Artemisinin-derived dimers have greatly improved anti-cytomegalovirus activity compared to artemisinin monomers | Q33815957 | ||
| Mutations in the human cytomegalovirus UL27 gene that confer resistance to maribavir | Q34437391 | ||
| A quantitative basis for antiretroviral therapy for HIV-1 infection | Q35812907 | ||
| Cytomegalovirus infection induces high levels of cyclins, phosphorylated Rb, and p53, leading to cell cycle arrest | Q35849687 | ||
| Artemisinin-derived dimer diphenyl phosphate is an irreversible inhibitor of human cytomegalovirus replication. | Q36086432 | ||
| Willmar Schwabe Award 2006: antiplasmodial and antitumor activity of artemisinin--from bench to bedside | Q36758444 | ||
| In vitro combination of anti-cytomegalovirus compounds acting through different targets: role of the slope parameter and insights into mechanisms of Action. | Q37544751 | ||
| Anticancer activities of artemisinin and its bioactive derivatives | Q37626137 | ||
| In vitro action of antiparasitic drugs, especially artesunate, against Toxoplasma gondii | Q39027347 | ||
| Cell cycle dysregulation by human cytomegalovirus: influence of the cell cycle phase at the time of infection and effects on cyclin transcription. | Q39578269 | ||
| Human cytomegalovirus infection inhibits cell cycle progression at multiple points, including the transition from G1 to S. | Q39877362 | ||
| Human cytomegalovirus infection inhibits G1/S transition. | Q39878302 | ||
| Success and failure of artesunate treatment in five transplant recipients with disease caused by drug-resistant cytomegalovirus | Q40229616 | ||
| Cyclin-dependent kinase activity is required for efficient expression and posttranslational modification of human cytomegalovirus proteins and for production of extracellular particles | Q40274359 | ||
| mRNA expression profiles for the response of human tumor cell lines to the antimalarial drugs artesunate, arteether, and artemether. | Q40712192 | ||
| Human cytomegalovirus inhibits cellular DNA synthesis and arrests productively infected cells in late G1. | Q41163429 | ||
| Biological mechanisms of action of novel C-10 non-acetal trioxane dimers in prostate cancer cell lines | Q41273184 | ||
| Inhibition of the cyclin-dependent kinases at the beginning of human cytomegalovirus infection specifically alters the levels and localization of the RNA polymerase II carboxyl-terminal domain kinases cdk9 and cdk7 at the viral transcriptosome | Q41770253 | ||
| Unique and highly selective anticytomegalovirus activities of artemisinin-derived dimer diphenyl phosphate stem from combination of dimer unit and a diphenyl phosphate moiety. | Q41830479 | ||
| Stability and antiviral activity against human cytomegalovirus of artemisinin derivatives. | Q42272265 | ||
| Recombinant luciferase-expressing human cytomegalovirus (CMV) for evaluation of CMV inhibitors | Q42616123 | ||
| Efficacy of artemisinin in experimental visceral leishmaniasis | Q43093287 | ||
| Antiviral activity of artesunate towards wild-type, recombinant, and ganciclovir-resistant human cytomegaloviruses. | Q43971464 | ||
| Monitoring cytomegalovirus infection by antigenemia assay and two distinct plasma real-time PCR methods after hematopoietic stem cell transplantation | Q44214552 | ||
| Orally active, antimalarial, anticancer, artemisinin-derived trioxane dimers with high stability and efficacy | Q44348694 | ||
| Molecular modes of action of artesunate in tumor cell lines. | Q44517624 | ||
| Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation | Q46639393 | ||
| The anti-malaria drug artesunate inhibits replication of cytomegalovirus in vitro and in vivo. | Q46834246 | ||
| Artesunate is ineffective in controlling valganciclovir-resistant cytomegalovirus infection | Q83355653 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Cytomegalovirus | Q6946 |
| artemisinin | Q426921 | ||
| P304 | page(s) | 3870-3879 | |
| P577 | publication date | 2015-04-13 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Inhibition of human cytomegalovirus replication by artemisinins: effects mediated through cell cycle modulation | |
| P478 | volume | 59 |
| Q39014776 | Artemisinin and its derivatives in treating protozoan infections beyond malaria |
| Q92809182 | Bright and Early: Inhibiting Human Cytomegalovirus by Targeting Major Immediate-Early Gene Expression or Protein Function |
| Q37397177 | Ebola VP40 in Exosomes Can Cause Immune Cell Dysfunction |
| Q58100736 | Inhibition of Cytomegalovirus Replication with Extended Half-Life Synthetic Ozonides |
| Q39044770 | Letermovir for the management of cytomegalovirus infection |
| Q89683934 | Orchestrated efforts on host network hijacking: Processes governing virus replication |
| Q47664127 | Peroxides with Anthelmintic, Antiprotozoal, Fungicidal and Antiviral Bioactivity: Properties, Synthesis and Reactions. |
| Q26740588 | Progress in Treatment of Viral Infections in Children with Acute Lymphoblastic Leukemia |
| Q56374730 | The Artemisinin Derivative Artemisone Is a Potent Inhibitor of Human Cytomegalovirus Replication |
| Q38797660 | Treatment of CMV infection after allogeneic hematopoietic stem cell transplantation. |
Search more.